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WHAT THIS PAPER ADDS?
 This is the ﬁrst investigation to our knowledge addressing the clinical signiﬁcance of upper-arm cephalic vein (UACV) patency in
radial-cephalic wrist ﬁstulas. The status of UACV in radial-cephalic arteriovenous ﬁstula is an important factor for clinical outcomes
such as maturation rate, interventional treatment needs, and long-term patency rate. When planning a radial-cephalic ﬁstula
placement, venous status including the UACV should be considered. Given the strong association of upper-arm cephalic venous
status with clinical outcomes, it is reasonable to assume that stenosis or occlusion of UACVs has certain hemodynamic disad-
vantages, even though the exact mechanism has not been clearly explained.a r t i c l e i n f o
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Objectives: To investigate the signiﬁcance of upper-arm cephalic veins (UACVs) in radial-cephalic arte-
riovenous ﬁstulas (RCAVFs), the medical records of 183 patients who had undergone RCAVF creation
were reviewed retrospectively.
Methods: The patients were divided into two groups according to the status of the UACV upon preop-
erative venography: group A of 153 cases (83.6%) with a patent UACV and group B of 30 cases (16.3%)
with a stenosed or occluded UACV. The clinical outcomes were compared.
Result: RCAVFs in group B had a signiﬁcantly higher maturation failure rate (26.7% vs. 9.8%, p ¼ 0.009) and
lower primary/secondary patency rates (log-rank test, p < 0.0001) than those in the group A. The
patients in group B required more frequent endovascular intervention to maintain access function
(p ¼ 0.002). The most common stenosis site was a draining vein in group B, in comparison to juxta-
anastomosis in group A. In the multivariate analyses, the status of the UACV was an independent
predictor of the primary and secondary patency rates of RCAVFs (p < 0.005).
Conclusion: UACV patency has a signiﬁcant impact on clinical outcome for RCAVFs. When planning an
RCAVF placement, venous status including the UACV should be considered.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Functional success is mainly determined by the status of the
selected vein and its outﬂow.1,2 Therefore, preoperative venous
imaging or mapping has been recommended in the guidelines set
by the National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (NKF K/DOQI) in all patients planned for hemo-
dialysis access.3 Various methods such as preoperative venous
mapping with ultrasonography4,5 and venography6,7 have been
advocated to increase the success rate and the prevalence of: þ82 31 219 4438.
ciety for Vascular Surgery. Publishautogenous ﬁstulas. In our institute, we have been using preoper-
ative ascending venography to determine the patency and
adequacy of superﬁcial and deep venous systems before creating an
arteriovenous ﬁstula. On venography, we occasionally found that
the forearm cephalic vein was suitable for a radial-cephalic arte-
riovenous ﬁstula (RCAVF) but the upper-arm cephalic vein (UACV)
was stenosed or occluded.
The role of the UACV in RCAVF in terms of the maturation rate
and patency outcomes has not been clearly deﬁned yet. To address
the question of whether UACVs would give a certain advantage in
hemodynamics, probably affecting clinical outcomes such as
maturation rates and patency rates after creating an RCAVF, weed by Elsevier Ltd. All rights reserved.
J.H. Lee et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 514e520 515analyzed and compared the clinical outcomes after creating an
RCAVF according to the status of the UACV.
Materials and Methods
Study design
We retrospectively reviewed the medical records and veno-
graphic images of 183 consecutive patients who underwent creation
of an RCAVF from March 2003 to February 2009. We created the
RCAVF using an autogenous cephalic vein and radial artery in an
end-to-side fashion. We excluded the cases of brachial-cephalic
ﬁstulas, radial-cephalic ﬁstulas with polytetraﬂuoroethylene (PTFE)
grafts, composite ﬁstulas with a PTFE graft segment, and venous-
transposed AVFs. Demographic variables such as age, gender, dia-
betes status, and use of anti-platelet agents were recorded and
analyzed. We divided the patients into two groups according to the
status of the UACV upon preoperative venography: group A with
a patent UACV and group B with a stenosed or occluded UACV.
We deﬁned “stenosed or occluded” UACVs as greater than 50%
stenosis or complete occlusion of the UACV between the ante-
cubital fossa and its termination in the axillary vein. Fig. 1 shows
schematic anatomy and nomenclature of upper-arm veins. Veno-
graphic examples are displayed in Fig. 2, which reveals a patent
(A-1, A-2) and a stenosed or occluded (B-1, B-2) UACV. Various
clinical outcomes such asmaturation failure rates and patency rates
were compared between the groups.
Functional maturation was deﬁned as successful cannulation of
the ﬁstula with ability of the access to deliver a ﬂow rate of 350e
400 ml/min and maintain dialysis for 4 h within 8 weeks of AVF
creation.8 The ﬂow rate during the hemodialyis had beenmeasured
by the nephrologists of the regional dialysis centers. The “primary
and secondary patency rates” were deﬁned according to the
guideline of the Society for Vascular Surgery.8
We also reviewed additional records of the patients who needed
endovascular interventions during the follow-up period, and
identiﬁed the locations of stenosis of AVF on ﬁstulography for the
patients who were referred from the local dialysis units for varied
reasons, such as inadequate blood ﬂow, increase access pressure,Figure 1. Diagram of upper-arm cephalic vein anatomy (Upper-arm cephalic vein
included median cephalic vein in this study).delayed hemostasis, arm edema, etc. Before the endovascular
interventions, physical examination and duplex ultrasound were
performed to evaluate the access, and ﬁstulography was performed
to conﬁrm the stenotic lesions. In cases of segmental stenosis of
more than 50% of diameter, with or without intra-access throm-
bosis, the endovascular interventions were indicated.
We sent a questionnaire to 91 dialysis centers to obtain follow-
up information, including the date of ﬁrst successful use of access,
the current function of the access, and the date of RCAVF failure.We
also gathered this information from the patients to verify it using
mobile phones. We collected and analyzed all 183 patients’ infor-
mation. We censored the follow-up in cases of patient death,
kidney transplantation, and change of dialysis methods. This study
has been approved by Institutional Review Board No.: AJRB-MED-
MDB-11-136.
Preoperative evaluation
To evaluate the arterial system of the upper extremity, we
carefully palpated brachial and radial arterial pulses, and examined
the arterial blood ﬂow in axillary, brachial, radial, and ulnar arteries
using a portable handheld Doppler system (Minidop ES-100VX;
Hadeco, Kawasaki, Japan). The Allen test was used to assess the
arterial competence of the palmar arch.
We also carefully examined the superﬁcial veins under visual
enhancement by placing a tourniquet on the upper arm while the
patient clenched and released his or her hand several times. We
used the ascending venography to determine the patency and
adequacy of the superﬁcial and deep venous systems as well as
central veins. During the patient and family conference before
venography, the patient was educated about the value of it and the
potential risks associated with contrast nephrotoxicity, contrast
extravasation, allergic reaction or anaphylaxis and other reactions,
and the informed consents were obtained. For venography, 25%
strength iso-osmolar contrast (Visipaque; GE Healthcare, Jupiter,
FL, USA) was used. Intravenous ﬂexible lines were placed by
nursing staff on the radial side of bilateral hands (for bilateral
studies). Venography was performed with high-quality digital
subtraction equipment with 14*17-inch image intensiﬁers (ALLURA
XPER FD 20; Philips, Hamburg, Germany) by a radiologist. A tour-
niquet was applied to the upper arm near the axilla, the veins were
ﬁlled with contrast agent, and unsubtracted digital spot images
were taken without magniﬁcation. Images were obtained from the
wrist veins to the right atrium. Additional images (i.e., oblique or
rotated arm projections) were obtained as needed to clearly
differentiate cephalic, brachial and basilic veins, especially in the
upper arms. Axillary and central venous images were done lastly
without a tourniquet application. The choice of operation for
creating an RCAVF was based on the overall assessment of a board-
certiﬁed vascular surgeon after evaluating all preoperative ﬁndings.
We were able to compare the diameter of veins with a cortical
thickness of background bone as a reference in venographic hard
copy. In adults, for example, the mean cortical thickness of the
proximal humerus is 4.4 mm.9 When the diameter was more than
about 2 mm without a stenosis, it was considered adequate.
Statistical analyses
Clinical data between the groups (group A with a patent UACV
and group B with an obliterated UACV) were compared using
Student’s t-test for continuous variables and chi-square test for
categorical variables. We calculated the patency outcome using the
KaplaneMeier method, and compared the patency rates using
the log-rank test. To identify the possible prognostic factors for the
primary and secondary patency rates of RCAVFs, we entered the
Figure 2. Preoperative ascending venography reveals patent (A), and stenosed or occluded (B) upper-arm cephalic veins. Figure A-1 and A-2 show the vein status of group A in the
antecubital fossa and in the shoulder, respectively. Figure B-1 and B-2 demonstrate the vein status of group B in the antecubital fossa and in the shoulder, respectively. Arrows
indicate the upper-arm cephalic vein.
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agents, side of the AVF, and status of the UACV, into a Cox regression
analysis. We used Statistical Package for the Social Sciences (SPSS)
18.0 software for Windows (SPSS Inc., Chicago, IL, USA). We
expressed all continuous variables as means  standard deviation,
and considered p values less than 0.05 as statistically signiﬁcant.
Results
Patient characteristics
During the study period, 535 series of venography were taken
before access creation. Three hundred and ﬁfty-two patients had
been selected for upper arm AVF (249 patients) or arteriovenous
graft (103 patients). One hundred and eighty-three cases of RCAVF
were included in this study. Among them, 153 (83.6%) patients had
patent UACVs (group A), whereas 30 (16.3%) had stenosed or
occluded UACVs (group B) on ascending upper-extremity venog-
raphy. The characteristics of the patients in the two study groups
are compared in Table 1. Variables such as patient age, diabetesstatus, use of anti-platelet agents, side of access placement were
not signiﬁcantly different between the groups (p > 0 0.05), except
for gender: there were more females than males in group B
(p ¼ 0.002). We followed all of the patients up at least for 24
months, and the mean follow-up periods were not different
between the two groups (45.5  20.4 [range, 24.8e100.3] months
vs. 48.7  26.7 [range, 25.1e102.1] months; p ¼ 0.461).
Preoperative venographic ﬁndings and the access creation
Among the 183 patients of this study population, 90 (49.2%)
patients had already been on dialysis before the creation of
radiocephalic ﬁstulas (63 patients on hemodialysis using
temporary catheter or permanent catheter, 19 patients on
hemodialysis using contralateral access, and 8 patients on peri-
toneal dialysis). The perforating, basilic vein, cubital vein, deep
vein and central vein in 153 patients of group A with patent
UACV were all patent. The perforating vein, basilic vein, cubital
vein, deep vein and central vein in 7 (23.3%) of 30 patients of
group B with stenosed or occluded UACVs were all patent. In 23
Table 1
Overall patient characteristics.
Characteristics Group A patent
UACV (n ¼ 153)
Group B stenosed
or occluded UACV
(n ¼ 30)
p-Value
Age (years) 56.4  13.9 57.5  13.0 0.679
Gender, No. (%) 0.002
Male 78 (51.0) 6 (20.0)
Female 75 (49.0) 24 (80.0)
Diabetes, No. (%) 83 (54.2) 20 (66.7) 0.210
Anti-platelets, No. (%) 40 (26.1) 13 (43.3) 0.058
RCAVF characteristics
Right/left side, No. 51/102 12/18 0.689
Mean follow-up, months 0.461
Mean  SD 45.5  20.4 48.7  26.7
Range (24.8e100.3) (25.1e102.1)
Maturation failure, No. (%) 15 (9.8) 8 (26.7) 0.009
Bold value signiﬁes the statisﬁcal signiﬁcance.
UACV, upper-arm cephalic vein; RCAVF, radial-cephalic arteriovenous ﬁstula.
Figure 3. KaplaneMeier curves showing primary (A) and secondary (B) patency rates
for radial-cephalic arteriovenous ﬁstulas with patent upper-arm cephalic veins
(n ¼ 153) and with stenosed or occluded upper-arm cephalic veins (n ¼ 30).
Table 2
Multivariate Cox regression analysis of the variables for the primary and secondary
patency rates.
Variables Primary patency Secondary patency
HR CI (95%) p-Value HR CI (95%) p-Value
Lower Upper Lower Upper
Female gender 0.934 0.579 1.506 0.779 1.044 0.460 2.369 0.918
Age 65 years old 1.422 0.902 2.239 0.129 2.675 1.240 5.775 0.012
Diabetes (þ) 1.523 0.948 2.448 0.082 1.294 0.598 2.799 0.513
Stenosed or
occluded UACV
2.710 1.576 4.657 <0.0001 3.304 1.451 7.524 0.004
Anti-platelets () 1.121 0.688 1.827 0.647 0.730 0.347 1.536 0.407
Right side RCAVF 1.070 0.661 1.731 0.784 1.766 0.841 3.706 0.133
Bold value signiﬁes the statisﬁcal signiﬁcance.
HR, hazard ratio; CI, conﬁdence interval; UACV, upper-arm cephalic vein; RCAVF,
radial-cephalic arteriovenous ﬁstula.
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stenosed or occluded. Eleven (36.7%) patients had completely
occluded UACVs, and 19 (63.3%) patients had more than 50%
stenosed UACVs. When the forearm cephalic vein was less than
2 mm in diameter or had a stenosis, it was not used for wrist
RCAVF creation.
Comparable data about renal function before and after the use of
contrast agent for venography were unavailable in this retrospec-
tive study. In ﬁve patients, contrast extravasation developed on the
puncture site. One patient complained of nausea, which improved
spontaneously. No other complications were noted during the
study period.
Maturation failure
The overall incidence of maturation failure within 8 weeks post
operation was 12.6% (23 cases), and was signiﬁcantly higher in
group B than in group A (26.7% vs. 9.8%, p¼ 0.009), as also displayed
in Table 1.
Primary patency and secondary patency
The mean primary patency of group A was signiﬁcantly longer
than that of group B (28.9  23.2 months vs. 17.0  21.7 months;
p ¼ 0.011). The mean secondary patency was not signiﬁcantly
different between group A and group B (36.6  22.7 months and
31.4  28.9 months; p ¼ 0.274).
Overall primary patency rates were 68.9% at 1 year, 63.4% at 2
years, and 59.3% at 3 years. Overall secondary patency rates were
89.9% at 1 year, 88.0% at 2 years and 86.3% at 3 years. Fig. 3 shows
that both the primary patency rate (A) and the secondary patency
rate (B) were signiﬁcantly higher in group A than those in group B
(log-rank test, p< 0.0001). The primary patency rates of group A vs.
group B were 73.5% vs. 43.5% at 1 year, 69.3% vs. 32.0% at 2 years,
and 64.9% vs. 30.6% at 3 years, respectively. The secondary patency
rates of group A vs. group B were 92.6% vs. 76.4% at 1 year, 91.9% vs.
67.3% at 2 years, and 90.6% vs. 64.2% at 3 years, respectively.
Multivariate analyses for patency outcome
We examined the variables of age 65 years, female gender,
diabetes, stenosed or occluded UACV, no anti-platelets and right
side RCAVF as possible risk factors for the primary and secondary
patency rates of RCAVF using multivariate Cox regression analyses.
We found that the variable of stenosed or occluded UACV was an
independent predictor for both the primary patency rate and thesecondary patency rate (HR 2.710, CI 1.576e4.657, p < 0.0001 for
the primary patency rate and HR 3.304, CI 1.451e7.524, p ¼ 0.004
for the secondary patency rate, respectively). The variable of age
65 years was also an independent predictor for the secondary
patency rate (HR 2.675, CI 1.240e5.775, p ¼ 0.012), as demon-
strated in Table 2.
Interventional treatments
Overall, 73 patients (39.9% of the study population) needed 109
endovascular interventions and 3 surgical interventions (2 anas-
tomosis revisions and 1 interposition graft).
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vascular interventions to maintain access function than those of
group A (p ¼ 0.002). Twenty patients (66.7% of group B) needed 36
endovascular interventions; 11 patients (36.7% of group B) needed
1 endovascular intervention, 4 patients (13.3% of group B) needed 2
endovascular interventions, and 5 patients (1.7% of group B) needed
more than 3 endovascular interventions.
The most common locations of stenosis, which could be the
main cause of access dysfunction, were signiﬁcantly different
between the groups. The stenosis was located in the juxta-
anastomosis area in 56 patients (76.7%) of group A, but in only 11
patients (30.6%) of group B (p< 0.0001). The stenosis was located in
a draining vein in 17 patients (47.2%) of group B, but in only 11
patients (15.1%) of group A (p < 0.0001). The major sites of endo-
vascular intervention were the juxta-anastomosis and draining
veins such as basilic veins and perforating veins. We did not
routinely try balloon angioplasty for the stenosed or occluded
UACVs. In three cases, balloon angioplasty was tried for an occluded
UACV. In two cases, we failed to pass a guide wire through the
occluded UACV due to a too tight stenosis. In one case, the blood
ﬂow was successfully restored through the UACV, and occluded
after 5 months of ﬂow restoration.
Discussion
As the mean age of patients depending on dialysis has increased
and the lifespan of the patients with renal failure has also
increased, the preservation of vessels for vascular access becomes
more important. Although direct autogenous arteriovenous ﬁstulas
on the wrist (RCAVF) are preferred, sometimes vascular conditions
are not suitable or not preferable. Anatomic factors such as diam-
eter or intimal thickness of feeding artery and draining vein have
been shown to be important predictors for the maturation and
patency of arteriovenous ﬁstulas.
In addition to a complete history and physical examination,
routine preoperative duplex ultrasonography (US) is recommended
by the NKF K/DOQI guidelines in all patients planned for hemodi-
alysis access.3 US mapping has the advantage of being noninvasive
while providingmore information than physical examination alone.
However, the role of US in predicting maturation varies in the
literature. VenographyafterUS could provide additional information
that changes the decision on adequacy of veins for ﬁstula creation.
This was reported by Huber et al,10 who described abnormalities
found through venography at the “optimal site” per previous US
examination that impacted the surgical plan and outcome. US is also
less sensitive than venography for examining the central veins.
Central venous stenosis must be inferred based on information not
supplied directly by the US examination.5 It is important to evaluateFigure 4. The incidence of endovascular interventions during the follow-up period
between the groups with patent and stenosed or occluded upper-arm cephalic veins in
radial-cephalic arteriovenous ﬁstulas (Chi-square test, p ¼ 0.002).if there is any suspicion of central venous stenosis, especially when
the patient is at risk of stenosis as a result of previous hemodialysis
or infusion catheter use, trauma or pacemakers.11e13
Preoperative venography studies require some form of contrast
medium. Some patients may be allergic to the contrast medium
used, and the use of contrast medium that can exacerbate renal
dysfunction in these patients may be undesirable.11,13,14 The NKF K/
DOQI guidelines give a caution against the use of contrast medium
for patients with renal insufﬁciency.15 However, several authors
have suggested that this risk is lower than previously thought
because the venography requires only small doses of contrast
medium.6,16 Asif et al.6 demonstrated that glomerular ﬁltration rate
did not decline at 48 h after radiocontrast administration in chronic
kidney disease stage 4 and 5 patients. As compared to the previous
results, two factors may explain the results of our study. First, a less
harmful agent of low-osmolarity contrast medium (LOCM) was
used for the venography. Second, and more importantly, the
dose used in this study was signiﬁcantly lower than that used in
the other studies describing the development of radiocontrast-
induced nephropathy. The results of our study demonstrated that
radiocontrast-induced acute renal failure did not develop when
10e20 cc of LOCMwas used even in high-risk patients. Theminimal
dose of contrast agent used during venography may be important
in minimizing the risk of nephrotoxicity.
Even though life-threatening complications associated with
radiocontrast media did not occur during the study period, serious
side effects such as impairment of renal function, anaphylactoid or
other allergic reactions, cardiovascular reaction, thromboembolism
and phlebitis should be considered during the use of contrast
media for venographic examination.
Even after adequate blood ﬂow was established with a success-
ful RCAVF, the modiﬁcation of hemodynamic factors played
a crucial role in vein wall remodeling on the site of dialysis. We
addressed the hypothesis that stenosed or occluded of UACV might
adversely affect the hemodynamic conditions in the draining vein,
and result in poor clinical outcomes after successful RCAVF.
In this study, we have shown that the stenosis or occlusion of
UACV had an impact on the clinical outcomes after RCAVF, as
follows: (i) maturation failure developed more frequently, (ii) the
rates of both primary patency and secondary patency were signif-
icantly inferior, (iii) more endovascular interventions were needed,
and (iv) the stenosis was most frequently located in the draining
vein rather than the juxta-anastomosis.
Though there is a relatively limited understanding of why
radial-cephalic ﬁstulas fail, the literature has provided insight into
the problem of maturation failure.
Several clinical studies have found that lesions of vascular
stenosis in patients with access failure were usually located within
the ﬁrst 5 cm of the venous segment.17e19 Roy-Chaudhury et al.19
postulated several pathophysiologic mechanisms for the early
failure of AVFs. Genetic predisposition, low shear stress, increases
in transmural pressure, turbulence, differences in compliance
between arteries and veins, and vascular injury of the mobilized
segment all contribute to the development of intimal hyperplasia
and adverse vascular remodeling. In one meta-analysis, RCAVFs
failed due to early thrombosis and poor maturation in 15.3% of
cases.20 In our study, maturation failure occurred in 12.5% of
RCAVFs, which frequently occurred in group B (26.7%). The patients
in group B needed more endovascular interventions to maintain
access function. Contrary to previous reports, in which the stenosis
was most frequently located in the juxta-anastomotic area,17,18 it
was most frequently located in the draining veins of the patients in
group B of our study population.
In the case of other factors, such as a peripheral location of the
ﬁrst ﬁstula, female sex, diabetes, and surgical expertise, which have
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demonstrate a difference in clinical outcomes in this study.
The patency outcome of AVFs for hemodialysis is quite variable,
lasting from days to years. The main cause of late ﬁstula failure has
been known to be thrombosis secondary to the development of
stenosis, caused by intimal hyperplasia or ﬁbromuscular thickening
of the vessel wall.22,23 We demonstrated that stenosis developed
more frequently in the draining vein in group B. This ﬁnding
suggests the possibility of hemodynamic disadvantage resulting in
intimal hyperplasia and development of stenosis in this type of
ﬁstula.
Though the overall primary and secondary patency rates of
RCAVFs at 12 months were comparable with those of other
reports,24,25 the patients in group B had signiﬁcantly lower rates of
primary patency and secondary patency (log-rank test, p < 0.001),
and required more frequent interventions until the last follow-up
(chi-square test, p ¼ 0.002). Moreover, in the multivariate anal-
ysis, the status of the UACV had a signiﬁcant impact on the rates of
both primary and secondary patency. The rates of primary and
secondary patency of RCAVFs with stenosed or occluded UACVs in
our studywere similar to those of forearm basilic vein transposition
AVFs in a recently reported study.26 The two types of AVFs seemed
to be similar in terms of geometric conﬁguration and hemodynamic
effect on the vascular wall.
The effect of sex on the rates of primary and secondary patency
has been examined in many studies.20,22,24,27 Several studies re-
ported that female sex was the only independent predictor of
decreased likelihood of ﬁstula maturation.25,26 In contrast, Rooijens
et al.20 and Prischl et al.27 found no signiﬁcant relation between
gender ratio and the rates of primary and secondary patency. In this
study population, gender distribution was signiﬁcantly different
between the groups (chi-square test, p¼ 0.002): female genderwas
dominant (80.0%) in the group with stenosed or occluded UACV.
However, we could not demonstrate that being female affected the
patency outcomes by both univariate and multivariate analysis
(p ¼ 0.551 by univariate analysis and p ¼ 0.779 by multivariate
analysis in primary patency, and p ¼ 0.271 by univariate analysis
and p ¼ 0.918 by multivariate analysis in secondary patency).
Conceivably, the effect of sex seen previously was mediated by
vessel status including patency of UACVs, which was accounted for
in our multivariable model.
With regard to age and access patency, several reports have
failed to ﬁnd any association between age and access complica-
tions,28e30 although others reported a signiﬁcant effect of age
appearing after 6 months of follow-up.31 Our results indicated that
age65 years was not a risk factor for the primary patency rate but
was so for the secondary patency rate.
Given the strong association of UACV status in RCAVFs with
these clinical outcomes, it is reasonable to assume that stenosed or
occluded UACVs have some hemodynamic disadvantages for the
clinical outcomes. It is difﬁcult to address this fact exactly, but we
canmake a reasonable inference with hemodynamic theories. Even
though UACVs were completely occluded, AV ﬁstula ﬂow could be
maintained when basilic veins were patent. However, the outﬂow
resistance of the ﬁstula and the intra-access pressure would be
greater in RCAVFs with stenosed or occluded UACVs than those
with patent UACVs. Such an increased access pressure or increased
resistance could lead to a harmful hemodynamic effect on access
patency. The high outﬂow resistance can cause an increased intra-
access pressure as well as a decreased ﬂow velocity. It is well
known that low velocity is related to low shear conditions, which
contribute toward intimal hyperplasia and vascular stenosis.
Unfortunately, we could not compare the exact hemodynamic
parameters such as the access pressure and the ﬂow velocity
between the two groups in this retrospective study.Our study had three main limitations. (i) The study groups were
too small to compare because stenosed or occluded UACVs in
RCAVFs are relatively uncommon. (ii) Our study did not collect data
on baseline vessel diameter or size. Even though we were able to
compare the diameter of veins with a cortical thickness of back-
ground bone as a reference in venographic hard copy, it is unclear
how closely this mimics our dialysis population or whether the
metabolic effects of chronic renal failure would inﬂuence these
determinations. Since we didn’t attempt to measure size against
a standard measure, the data is of limited value and may not
provide useful information to generalize the ﬁndings to other
practice situations. However, it could be useful to determine
whether the vein was suitable for AVF creation or not. (iii) Even
though the clinical results were statistically signiﬁcant, direct
hemodynamic parameters such as static intra-access pressure,
access ﬂow rate and measured wall shear stress were not
represented.
In conclusion, our study shows that the stenosed or occluded
UACV in RCAVFs may be related to inferior clinical outcomes, in
terms of maturation, patency rate and frequency of stenosis
development. When planning RCAVF placements, venous status
(including that of the UACV) should be considered. For RCAVFs with
stenosed or occluded UACVs, close surveillance is required to
maintain their long-term patency.
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